Skip to content
Abilene News

Moderna-Merck personalized mRNA melanoma vaccine cuts relapse risk in late-stage trial

Moderna-Merck personalized mRNA melanoma vaccine cuts relapse risk in late-stage trial
Photo: KTXS (ABC 12) Abilene News · view original

A personalized melanoma vaccine combined with Keytruda cut the risk of cancer returning or death by 42% in a late-stage trial, Moderna and Merck said.

Sources and story details